A Phase 1, Single-center, Open-label Pharmacokinetic, Safety and Tolerability Study of SB204 in Adolescents With Moderate to Severe Acne Vulgaris
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 27 Apr 2017
At a glance
- Drugs Nitric oxide (Primary)
- Indications Acne vulgaris
- Focus Pharmacokinetics
- Sponsors Novan Inc
- 27 Apr 2017 Results from this trial will be presented at the 76th Annual Meeting of the Society for Investigative Dermatology 2017, as per a Novan therapeutics media release.
- 03 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Jun 2017.
- 03 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2017.